Therapeutic effect of pertuzumab combined with albumin-bound paclitaxel and carboplatin in patients with human epidermal growth factor receptor 2-positive advanced breast cancer
Objective To explore the therapeutic effect of pertuzumab combined with albumin-bound paclitaxel and carboplatin in patients with human epidermal growth factor receptor 2(HER2)-positive advanced breast cancer.Method According to different treatment methods,108 patients with HER2-positive advanced breast cancer were divided into ob-servation group(n=63)and control group(n=45).Patients in the control group were treated with albumin-bound paclitax-el combined with carboplatin,and patients in the observation group were treated with pertuzumab combined with albu-min-bound paclitaxel and carboplatin.The tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 15-3(CA15-3)]levels,vascular endothelial growth factor(VEGF)levels,clinical effica-cy and adverse reactions were compared between the two groups.Result After treatment,the CEA,CA125,CA15-3,VEGFA and VEGFB levels in both groups were lower than those before treatment,and the CEA,CA125,CA15-3,VEGFA and VEGFB levels in observation group were lower than those in control group,and the differences were statisti-cally significant(P＜0.05).The disease control rate of observation group was higher than that of control group,and the dif-ference was statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse reac-tions between the two groups(P＞0.05).Conclusion Pertuzumab combined with albumin-bound paclitaxel and carboplat-in have significant efficacy in the treatment of HER2-positive advanced breast cancer patients,which can reduce the lev-els of tumor markers and VEGFA,VEGFB,and has a certain safety.
pertuzumabalbumin-bound paclitaxelcarboplatinhuman epidermal growth factor receptor 2ad-vanced breast cancer
万方数据
维普
